We previously reported that phosphorylation of topoisomerase (topo) IIa at serine-1106 (Ser-1106) regulates enzyme activity and sensitivity to topo II-targeted drugs. In this study we demonstrate that phosphorylation of Ser-1106, which is flanked by acidic amino acids, is regulated in vivo by casein kinase (CK) Id and/or CKIe, but not by CKII. The CKI inhibitors, CKI-7 and IC261, reduced Ser-1106 phosphorylation and decreased formation of etoposide-stabilized topo II-DNA cleavable complex. In contrast, the CKII inhibitor, 5,6-dichlorobenzimidazole riboside, did not affect etoposide-stabilized topo II-DNA cleavable complex formation. Since, IC261 specifically targets the Ca 2+ -regulated isozymes, CKId and CKIe, we examined the effect of down-regulating these enzymes on Ser-1106 phosphorylation.
INTRODUCTION
Type II DNA topoisomerases, topoisomerase II (topo II) a and b, regulate DNA topology by creating transient double stranded DNA breaks (1) (2) (3) . Although, both enzymes exhibit significant sequence homology and catalyze redundant catalytic reactions, they are involved in different cellular functions. This difference may in part be due to differential regulation of these enzymes. Several different mechanisms have been shown to regulate topo II activity, including transcriptional, translational, as well as post-translational mechanisms. The major posttranslational mechanisms that modulate topo II activity are phosphorylation, interaction with other proteins and proteasome-mediated degradation (1) (2) (3) .
Both topo IIa and topo IIb are phosphorylated at several sites, primarily in the divergent C-terminal region (4) (5) (6) (7) (8) . Whereas, little is known about site-specific phosphorylation of topo IIb, several in vitro and in vivo studies have identified specific phosphorylation sites in topo IIa. Within the C-terminal region of topo IIa phosphorylation of threonine-1342, serine(Ser)-1376, Ser-1469 and Ser-1524 catalyzed by casein kinase (CK) II (6, (9) (10) (11) (12) (13) (14) , and of Ser-1212, Ser-1246, Ser-1353, Ser-1360 and Ser-1392 catalyzed by a proline directed kinase has been observed (15) . Recently, it has been reported that Polo-like kinase 1 phosphorylates topo IIa at Ser-1337 and Ser-1524 (16) .
In addition to the sites in the C-terminal region, phosphorylation of Ser-29 located in the ATP binding domain within the N-terminal region (17) and of Ser-1106 located within the catalytic core have also been reported (18) . Whereas phosphorylation of Ser-29 is catalyzed by protein kinase C (17) , the kinase responsible for phosphorylation of Ser-1106 has not yet been identified.
Since Ser-1106 is located in the catalytic domain of topo IIa and phosphorylation of this site enhances enzyme activity and sensitivity to topo II-targeted drugs in vivo (18) , it is important to decipher the mechanism by which phosphorylation of Ser-1106 is regulated. The first step toward determining this mechanism would be to identify the kinase(s) that catalyzes phosphorylation at this site. Based on the acidic amino acid sequences that flank Ser-1106 at the amino-and carboxy-terminus, two potential kinases that could phosphorylate this site are CKI and CKII (19) . Although CKII has been recognized as a major kinase phosphorylating topo IIa, the role of CKI in phosphorylating topo IIa has not been explored. Unlike CKII, which consists of a tetramer of two catalytic subunits, a and/or a 0 , and two regulatory b subunits (20) (21) (22) , human CKI comprises of a superfamily of seven different isozymes that function as monomers (23, 24) . Structurally these isozymes, CKIa, b, g1, g2, g3, d and e, are organized into three distinct regions -a short N-terminal region, a highly conserved kinase domain and a highly variable C-terminal domain, primarily involved in regulating enzyme function. The CKId and CKIe isozymes are very similar in structure and exhibit 98% homology in the kinase domain and 50% homology in the C-terminal domain. Autophosphorylation of the C-terminal domain leads to inhibition of the enzyme, which can be relieved following dephosphorylation or proteolytic cleavage of this region, often via a Ca 2+ -dependent mechanism (25, 26) . Indeed, it has been suggested that dephosphorylation of CKIe by the Ca 2+ /calmodulin-dependent phosphatase, calcineurin, enhances phosphorylation of DARP-32 by this isozyme (27, 28) .
Our earlier studies demonstrating a Ca
2+
-dependent mechanism in regulating phosphorylation of Ser-1106 and in modulating sensitivity to topo II-targeted drugs (18) suggested that the kinase responsible for phosphorylating this site may be CKId and/or CKIe, rather than CKII. In this study we examined the role of CKId/e and CKII in phosphorylating Ser-1106 by attenuating the activity of these kinases with specific inhibitors or with targeted si-RNAs. Our results demonstrated that CKId/ e, but not CKII, catalyzes the in vivo phosphorylation of Ser-1106 and regulates topo II-DNA cleavage activity. C in a humidified atmosphere of 5% CO 2 and 95% air. Cells were treated with CKI-7 (200 mM), IC261 (10 mM) or DRB (40 mM) for 3 h. When the combination of CKI or CKII inhibitor and etoposide was employed, cells were pretreated with CKI-7, IC261 or DRB for 3 h. Following this treatment, cells were washed, resuspended in inhibitor-free medium and incubated for an additional hour in etoposide.
MATERIALS AND METHODS

Reagents
Transfection with targeted si-RNAs
A 21-nucleotide duplex si-RNA (si-CKId/e) with the sequence sense: 5 0 -CUGGGGAAGAAGGGCAACCd TdT-3 0 and antisense: 5 0 -GGUUGCCCUUCUUCCCC AGdTdT-3 0 , purchased from Qiagen, Valencia, CA, USA was used to target identical regions in CKId and CKIe (29) . In addition the On-Target plus SMART pool si-RNA anti-CSNKID human (si-CKId) and On-Target plus SMART pool si-RNA anti-CSNKIE human (siCKIe) were purchased from Dharmacon, Lafayette, CO. For targeting CKIIa RNA the siGENOM SMART pool CSNK2A1 (Dharmacon, Lafayette, CO) was employed. The CKIIa 0 si-RNA (sense: 5 0 -CAGUCUG AGGAGCCGCGAGdTdT-3 0 , antisense: 5 0 -CGGCUCC UCAGACUGdTdT-3 0 ), previously described (30) was synthesized by MWG Biotech, Ebersberg, Germany. The control si-RNA (5 0 -GCUCAGAUCAAUACGGAGAdT dT-3 0 ) was purchased from Dharmacon, Lafayette, CO. HCT-116 cells were incubated in serum-free McCoy's medium for 6-10 h with the si-RNA (100 nM) in the presence of Lipofectamine 2000 (Invitrogen Life Technology, Carlsbad, CA) as described by the manufacturer. When the combination of si-CKId and si-CKIe was employed, the concentration of each si-RNA was reduced to 75 nM. Following the initial incubation, cells were washed and cultured in McCoy's medium containing 10% fetal bovine serum and 2 mM L-glutamine for 24 h. At the end of the incubation period, cells were harvested for preparing cell lysates. When cells were transfected with si-CKId/e about 50-70% of the cells that readily detached upon washing were used for preparing lysates for 2D-phosphopeptide maps of topo IIa, since both CKId and CKIe were maximally down-regulated in this population.
Transformation of Sachharomyces cerevisiae W303 cells
The wild-type (WT) S. cerevisiae W303 strain (ura3-1, trp1-1, leu 2-3, 112, his3-11, 15 can1-100, ade2-1) and 7D, an HRR25D isolate isogenic to W303 (31) kindly provided by Dr Anthony DeMaggio (ICOS, Corp., Bothell, WA) were transformed with human topo IIa cDNA cloned in the pHT212 vector using the Yeastmaker lithium acetate transformation system (Clontech, Palo Alto, CA). Control transformations were carried out with the pHT212 plasmid (LEU2). Cells transformed with the pHT212 plasmid or pHT212 plasmid with the human topo IIa insert were selected on plates lacking leucine (18 for an additional 3 h. During the labeling period, the CKI or CKII inhibitor was added for experiments involving these treatments. Yeast cells were labeled as previously described (18) . Briefly, cells cultured overnight at 308C with shaking (250 rpm) in synthetic dropout liquid medium lacking leucine were incubated in YPDA without phosphate medium, for 3 h with shaking, to a cell density corresponding to 0.6 units (A600). Following centrifugation, cells were resuspended into 20 ml of YPDA medium without phosphate containing 5 mCi of [ 32 P]-orthophosphoric acid and incubated at 308C for 1 h with shaking.
Preparation of cell lysates, immunoprecipitation and western blotting
Lysates of HL-60 and HCT-116 cells were prepared in radioimmunoprecipitation assay (RIPA) buffer as described earlier (18) . Topo IIa protein immunoprecipitated from the cell lysate was subjected to SDSpolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membrane (18) . The membrane was stained with Gelcode Blue staining reagent (Pierce Chemical Co., Rockford, IL) to visualize the topo IIa band, which was excised and processed for proteolysis with cyanogen bromide (CNBr) or trypsin (18) . For determination of down-regulation of CKId and CKIe, western blot analysis was carried out on cell lysates (20-40 mg) prepared from si-RNA transfected cells that were harvested just prior to labeling with [ 32 P]-orthophosphoric acid (32) . Cell lysate of S. cerevisiae cells were prepared in Y-PER lysis buffer after freezing the cell pellet in liquid nitrogen and human topo IIa present in the lysate was purified by Ni 2+ -nitrilotriacetic acid essentially as described earlier (18) . Purified topo IIa was subjected to SDS-PAGE, transferred to nitrocellulose membrane and the stained topo IIa band was processed for phosphopetide mapping.
Phosphopeptide mapping of 32 P-labeled topo IIa
The 170 kDa 32 P-labeled topo IIa band visualized by staining with Gelcode Blue staining reagent on the nitrocellulose membrane was excised and digested with trypsin essentially as described earlier (18) . led to generation of a single Ser-1106 containing peptide. The tryptic peptides released in the ammonium bicarbonate solution were transferred to fresh microcentrifuge tube and the membrane piece was washed with 100 ml of 20% acetonitrile. The pooled eluate and washings were then concentrated by evaporation in a Savant SpeedVac, washed three times with water and the peptides solubilized in pH 1.9 buffer (88% formic acid/glacial acetic acid/deionized water, 1:3.1:36, v/v). The peptides were then separated on thin layer cellulose plates by electrophoresis with pH 1.9 buffer in the horizontal dimension and chromatography in the vertical dimension (33) . In initial experiments the phospho-chromatography buffer contained n-butanol/pyridine/acetic acid/deionized water (5/3.3/1/4, v/v). To improve migration of the Ser-1106-peptide an isobutyric acid buffer (isobutyric acid/n-butanol/pyridine/acetic acid/deionized water) (32.9/1/2.5/1.5/ 14.7, v/v), which resolves extremely hydrophilic phosphopeptides, was used.
Liquid chromatography-tandem mass spectrometry (LC-MS)
LC-MS was carried out on tryptic digests of stained topo IIa protein band excised from SDS-polyacrylamide gels. In-gel trypsin digestion was carried out as described earlier (34) . Briefly, following washing/destaining in two aliquots of 50% ethanol/5% acetic acid (v/v), reduction with dithiothreitol and alkylation with iodoacetamide, the excised gel pieces were dried in a Speed-vac and incubated with 30 ml of 20 ng/ml trypsin in 50 mM ammonium bicarbonate on ice for 10 min. Any excess trypsin solution was then removed and 20 ml of 50 mM ammonium bicarbonate was added. Following overnight digestion at room temperature, the peptides were extracted from polyacrylamide pieces in two 30 ml aliquots of 50% acetonitrile/5% formic acid (v/v). These extracts were combined and evaporated to $5 ml and then reconstituted in 1% acetic acid to a total volume of 25 ml for LC-MS analysis. The tryptic peptides in the extract (2 ml/injection) were separated by reversedphase LC in a 10 cm Â 50 mm (i.d.) Phenomenex Jupiter 10 mm C18 self-packed capillary column using a linear gradient of 2-70% acetonitrile containing 0.05 M acetic acid in 50 min at a constant flow rate of 0.2 ml/min. The effluent was analyzed using a Finnigan LCQ-Deca ion trap mass spectrometry system equipped with a Protana microelectrospray ion source (ThermoFisher, San Jose, CA) operated at 2.5 kV. Data interpretation was performed with the programs TurboSequest and Mascot. All matching spectra were verified by manual interpretation.
Selected reaction monitoring (SRM) mode was used to compare the extent of Ser-1106 phosphorylation in control scrambled si-RNA and si-CKId/e treated HCT-116 cells. The SRM experiment consisted of a 5-scan event analysis in which one scan event was a standard MS scan and the other four were different SRM descriptors directed to various sets of control or Ser-1106 containing peptides, both unphosphorylated and phosphorylated. To verify peptide recovery from the digestion procedure and the mass spectrometry response, one ion of the trypsin autolysis peptide VATVSLPR at m/z 422 (+2) and one ion of the unmodified topo IIa native peptide EVTFVPGLYK at m/z 577 (+2) were monitored. These two descriptors served as controls. In addition, the ion transition m/z 484 ! m/z 435 (+2) characteristic for phosphate loss from phosphorylated Ser-29 contained in RLpS 29 VER peptide in topo IIa was monitored to confirm general phosphorylation of every sample. To determine the status of Ser-1106 phosphorylation, the peptide VPDEEENEES 1106 DNEKETEK containing phosphorylated Ser-1106 as doubly charged (m/z 1116) or triply charged (m/z 744) ion and their corresponding unphosphorylated peptide ions were monitored.
DNA cleavable complex formation
The effect of etoposide on forming a stable topo II-DNA cleavable complex was determined by measuring the amount of precipitated protein-DNA complex and by evaluating depletion of topo IIa not complexed with DNA (band depletion). For measuring precipitated protein-DNA complex, cells were labeled for 24 h with 0.02-0.04 mCi/ml of [
14 C]-thymidine, specific activity 53 mCi/mmol (Amersham, Arlington Heights, IL). For measuring DNA cleavable complex in cells downregulated for CKId plus CKIe, cells were treated for 6 h with scrambled si-RNA or si-CKId plus si-CKIe prior to labeling. Cells were then trypsinized, treated with etoposide for 1 h and the precipitated protein-DNA complex was assayed as previously described (35) . For the band depletion experiment cells were treated similarly without the addition of [
14 C]-thymidine. Cell lysates were prepared in 2-fold concentrated LDS-sample buffer (Invitrogen Life Technology, Carlsbad, CA, USA). The lysates were incubated at 70 8 C for 10 min, sonicated and centrifuged at 12 000 Â g. An aliquot (10-15 ml) of the lysate was subjected to western blot analysis. The membranes were probed with antibodies to topo IIa and topo I (internal control), which does not form a stabilized DNA cleavable complex with the topo II-targeted drug, etoposide. Down-regulation of CKId and CKIe was also determined by western blotting with antibodies specific for CKId and CKIe.
RESULTS
Inhibitors of CKId and CKIe (CKI-7 and IC261) lead to hypophosphorylation of the CNBr and tryptic topo IIa peptides containing Ser-1106 and reduce formation of etoposide stabilized topo II-DNA cleavable complex
The presence of acidic amino-acid residues N-terminal to Ser-1106 and the Ca 2+ -dependency of phosphorylation of this site (18) suggested that phosphorylation of Ser-1106 may be regulated by protein kinase CKId and/or CKIe. Therefore we first examined whether two CKI inhibitors, CKI-7 and IC261, specific for CKId and CKIe (36) , altered phosphorylation of Ser-1106 containing peptides. Treatment of HL-60 cells with CKI-7 or IC261 led to hypophosphorylation of the CNBr (peptide 34) and tryptic phosphopeptides that were previously shown to harbor Ser-1106 ( Figures 1A and 1B, respectively) . Comparison of the intensity of spots corresponding to the peptides containing Ser-1106 (normalized to two other peptides) revealed that CKI-7 and IC-261 led to comparable decreases (20-40% and 25-30%, respectively) in phosphorylation of Ser-1106 as compared to untreated control cells. To determine whether decreased phosphorylation observed in the presence of CKI-7 or IC261 compromises the functional activity of topo IIa, we examined the effect of CKI-7 and IC261 on formation of etoposide stabilized topo II-DNA cleavable complex. Pre-treatment of HL-60 cells with 200 mM CKI-7 or 10 mM IC261 for 3 h prior to treatment with 5 mM etoposide for 1 h led to a significant (P < 0.05) decrease in the formation of etoposide-stabilized DNA cleavable complex (Figure 2) . We also examined the effect of the CKII specific inhibitor, DRB, on formation of etoposide stabilized topo II-DNA cleavable complex. Pretreatment with 40 mM DRB did not alter etoposide stabilized topo II-DNA cleavable complex formation (Figure 2) . These results suggest a role for CKId/e in regulating the functional activity of topo IIa via phosphorylation at Ser-1106.
Down-regulation of CKId and/or CKIe with targeted si-RNA decreases phosphorylation of the tryptic peptide containing Ser-1106
To confirm the role of CKId and/or CKIe in phosphorylating Ser-1106 we down-regulated these two enzymes with three different sets of si-RNAs. These included si-CKId/e-which targeted the nucleotide sequence (412-430) that is identical in the CKId and CKIe coding region; si-CKId-which is a smart pool targeted to the CKId isozyme; and si-CKIe-which is a smart pool targeted to the CKIe isozyme. The si-CKId and si-CKIe were used individually to down-regulate the specific isozyme or used in combination to simultaneously down-regulate both isozymes. Since, HL-60 cells are difficult to transfect we used the colon carcinoma cell line, HCT-116, for transfection of the si-RNAs. This cell line was chosen because it can be readily transfected and the phosphopeptide map of topo IIa in HCT-116 cells is similar to that in HL-60 cells (data not shown). Transfection of the three si-RNAs in HCT-116 cells led to significant down-regulation ($60-80%) of the targeted isozyme; siCKId/e and the combination of si-CKId and si-CKIe led to down-regulation of both CKId and CKIe, whereas siCKId or si-CKIe when used individually, down-regulated only the targeted enzyme CKId or CKIe, respectively ( Figures 3A, 5A and 8A ). When both CKId and CKIe were down-regulated a slight increase in the G 2 + M phase of the cell cycle was observed (data not shown).
The down-regulation of CKId and CKIe in HCT-116 cells transfected with si-CKId/e resulted in significantly decreased (75%) phosphorylation of the tryptic Ser-1106 containing phosphopeptide, as compared to cells transfected with the control scrambled si-RNA ( Figure 3B ). This was not due to an increase in the G 2 + M population observed in cells transfected with si-CKId/e, since phosphorylation at Ser-1106 was not affected when cells were blocked in mitosis following treatment with nocadazole ( Figure 3C ). Comparison of phosphorylation of Ser-1106 in topo IIa present in cells transfected with scrambled si-RNA or si-CKId/e by LC-MS (Figure 4 ) revealed findings that were similar to those obtained by 2D-phosphopeptide mapping. Although both phosphorylated and unphosphorylated Ser-1106 was detected in control cells transfected with scrambled si-RNA, only unphosphorylated Ser-1106 was detected in cells transfected with si-CKId/e. Down-regulation of only one isozyme, CKId or CKIe ( Figure 5A ), also led to hypophosphorylation of the Ser-1106 containing peptide ( Figures 5B and 5C , respectively), albeit to a lesser extent than that observed when both CKId and CKIe were down-regulated ( Figure 3B ). In cells treated with si-CKId, phosphorylation of Ser-1106 was 25-40% less than that observed in cells treated with scrambled si-RNA, whereas in cells treated with si-CKIe phosphorylation of Ser-1106 was 40-65% less than that observed in cells treated with scrambled si-RNA. Differential hypophosphorylation of Ser-1106 in si-CKId and si-CKIe transfected cells could be due to differences in the effectiveness of the two isozymes in phosphorylating this site or due to differential down-regulation of CKId ($60%) and CKIe ($80%).
To confirm that phosphorylation of Ser-1106 in vivo does not involve CKII we examined the effect of transfecting HCT-116 cells with si-RNAs to CKIIa and CKIIa 0 on phosphorylation of Ser-1106. Results of this experiment revealed that transfectants, in which CKIIa and CKIIa 0 were significantly down-regulated ( Figure 6A ), did not exhibit altered phosphorylation of Ser-1106 although phosphorylation of other tryptic peptides previously C-thymidine were pre-incubated in the absence or presence of CKI-7 (200 mM), IC261 (10 mM) or DRB (40 mM) for 3 h at 37 8 C. Cells were then washed, resuspended in inhibitor-free medium and incubated for an additional hour in etoposide (5 mM). Control, labeled cells were incubated in the presence of medium alone. The labeled DNA was precipitated with SDS-KCl as described in Materials and methods section and the dpm in the precipitate was determined by liquid scintillation counting. DNA cleavable complex formation in the etoposide or inhibitor ! etoposide treatment was determined by calculating the ratio of dpm in treated cells to control cells.
Ã Significantly (P < 0.05) lower than treatment with etoposide alone.
reported to be substrates for casein kinase II (6) was reduced ( Figure 6B ).
Phosphorylation of Ser-1106 in human topo IIa expressed in HRR25" S. cerevisae cells is reduced, but can be enhanced following transformation of the cells with human CKIe
Since human topo IIa expressed in S. cerevisiae cells is phosphorylated at Ser-1106 (18) and the S. cerevisiae gene, HRR25 is homologous to CKId and CKIe (37), we compared phosphorylation of Ser-1106 in WT or HRR25Á cells transformed with human topo IIa. As shown in Figure 7A , phosphorylation of the tryptic Ser-1106 peptide was significantly reduced in HRR25Á cells. Transformation of the HRR25Á cells expressing human topo IIa with human CKIe enhanced phosphorylation at Ser-1106 ( Figure 7B ). This finding provides further support for the role of CKId/e, in particular the CKIe isozyme, in regulating phosphorylation at Ser-1106 in topo IIa.
Reduced phosphorylation of Ser-1106 in HCT-116 cells transfected with si-CKId plus si-CKIe leads to decreased formation of etoposide stabilized topo II-DNA cleavable complex
We previously demonstrated a functional role for Ser-1106 phosphorylation in topo IIa, based on the observation that mutation of Ser-1106 to alanine in human topo IIa led to decreased topo IIa function in vitro and in vivo in JN394 yeast cells transformed with human topo IIa (18) . In this study we examined whether topo IIa function is affected when phosphorylation at Ser-1106 is altered by down-regulating the kinase(s), CKId and/or CKIe, involved in phosphorylating this residue. Down-regulation of CKId and CKIe by si-CKId plus si-CKIe ( Figure 8A ) led to a significant (P < 0.01) decrease in SDS-KCl precipitable 14 C-thymidine labeled etoposide stabilized topo II-DNA cleavable complex ( Figure 8B P] orthophosphoric acid for 3 h. At the end of the incubation, cells were lysed in RIPA buffer and cell lysates were immunoprecipitated with topo IIa-specific antibodies. The immunoprecipitated topo IIa protein was subjected to SDS-PAGE and transferred to nitrocellulose membrane. The topo IIa band was excised, proteolysed with trypsin and the labeled tryptic peptides analyzed by 2D-phosphopeptide mapping. The isobutyric acid buffer (isobutyric acid/n-butanol/pyridine/acetic acid/deionized water) (32.9/1/2.5/1.5/ 14.7, v/v) was used for resolving the peptides in the second dimension. The arrow indicates the position of Ser-1106 containing peptide.
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Relative Abundance (%) is also hypophosphorylated, and phosphorylation at this site can be enhanced following transformation of these cells with human CKIe. The decrease in phosphorylation of the Ser-1106 tryptic peptide is indeed due to reduced phosphorylation at this site, since our earlier studies indicated that in vivo phosphorylation of this tryptic peptide was not observed when Ser-1106 in topo IIa was mutated to alanine (18) . Several different kinases, including CKII, protein kinase C, proline directed kinases e.g. cdc2 and Polo-like kinase 1 have been reported to phosphorylate topo IIa (6, (9) (10) (11) (12) (13) (14) (15) (16) (17) . However, this is the first report demonstrating CKI as a physiologically relevant kinase that modulates phosphorylation and activity of topo IIa. Our data demonstrating decreased phosphorylation of several peptides (excluding the Ser-1106 containing peptide) following downregulation of CKIIa and CKIIa 0 with targeted si-RNAs provides evidence that CKII is also capable of phosphorylating topo IIa in vivo. However, phosphorylation at CKII sites does not significantly affect sensitivity to topoII-targeted drugs, since treatment of HL-60 cells with the CKII inhibitor, DRB, did not significantly alter formation of topo II-drug-DNA complex in vivo. Since our study did not evaluate the effect of reduced phosphorylation at CKII sites on other functions of topo IIa, the functional role of phosphorylations at CKII sites remains unclear. It is possible that phosphorylation at CKII sites, most of which map to regions in the C-terminal domain, along with other phosphorylations within this region regulate accessibility of the catalytic site to its substrate. This mechanism would be analogous to that described for regulation of the activity of CKId and CKIe, wherein dephosphorylation of the C-terminal region activates the enzyme.
Our previous data demonstrating Ca 2+ -dependent phosphorylation of Ser-1106 (18), provides further support for the role of CKId and/or CKIe (Ca 2+ -regulatable enzymes), but not CKII, as physiologic kinases that modulate Ser-1106 phosphorylation. Although, the catalytic activity of CKId and CKIe does not require Ca 2+ , these enzymes can be regulated via Ca 2+ -dependent dephosphorylation or proteolysis (25, 26) . In neostriatal neurons, the metabotrophic glutamate receptors activate CKIe by dephosphorylating the inhibitory C-terminal autophosphorylation sites by the Ca 2+ -dependent phosphatase, calcineurin (38) . The activated CKIe then leads to phosphorylation of Ser-137 of DARPP-32. A scenario similar to that described in neostriatal muscles, could explain how phosphorylation of Ser-1106 is regulated by Ca 2+ . Dephosphorylation by calcineurin and subsequent activation of CKId and/or CKIe could result in phosphorylation of Ser-1106. Alternatively, a Ca 2+ -dependent protease, e.g. calpain, which is activated by calcium influx in neurons (27, 39) , could remove the inhibitory -nitrilotriacetic acid or immunoprecipitated with topo IIa antibody. Purified topo IIa was subjected to SDS-PAGE and transferred to nitrocellulose membrane. The stained topo IIa band was excised, proteolysed with trypsin and the labeled tryptic peptides analyzed by 2D-phosphopeptide mapping. The phosphochromatography buffer, n-butanol/pyridine/acetic acid/deionized water (5/3.3/1/4, v/v), was used for separating the peptides in the second dimension (A) and the isobutyric acid buffer (isobutyric acid/n-butanol/pyridine/ acetic acid/deionized water) (32.9/1/2.5/1.5/14.7, v/v) was used for resolving the peptides in the second dimension (B). The arrow indicates the position of Ser-1106 containing peptide. domain in CKId or CKIe and lead to activation of these kinases.
CKI isozymes are involved in regulating several different cellular processes (40) . The CKId and CKIe isozymes have been shown to modulate the development process because of their role in the wnt signaling pathway. In addition, these isozymes play a role in circadian rhythm, cell division, apoptosis and neurodegenerative diseases. CKId and CKIe phosphorylate p53, tubulin and microtubule-associated proteins to regulate cell growth, chromosome segregation and stress response at the spindle apparatus and the mitotic centrosome. The identification of topo IIa, which is also involved in regulating DNA replication and cell division, chromosome segregation and DNA repair, as another nuclear substrate of CKId and/or CKIe in this study, suggests that these CKI isozymes may be essential for regulating various aspects of DNA metabolism. In this regard, topo IIa could function as part of a protein complex that comprises of transcription factors, nuclear regulatory proteins and kinases (including CKId and/or CKIe)/phosphatases that regulate phosphorylation/dephosphorylation of components of the complex. Thus, it would be important to determine whether CKId or CKIe is capable of associating with topo IIa.
In summary our results demonstrate that CKId and/or CKIe are physiologically relevant kinase(s) that are involved in regulating site-specific phosphorylation at Ser-1106 and modulating the function of topo IIa. Since Ser-1106 phosphorylation regulates sensitivity of cells to topo II-targeted drugs and expression of CKId and/or CKIe can be altered in cancer cells, one potential mechanism by which tumor cells develop resistance to topo II-targeted drugs could involve decrease in expression or activation of CKId and/or CKIe. The correlation of Ser-1106 hypophosphorylation with etoposide resistance was not only observed in cell culture model systems but was also seen in blast cells isolated from patients with acute myelogenous leukemia. Comparison of Ser-1106 phosphorylation with etoposide induced apoptosis revealed that reduced phosphorylation at Ser-1106 was associated with decreased apoptosis (data not shown). Thus, it might be possible to identify sensitivity of tumors to topo IIa-targeting drugs by characterizing phosphorylation at Ser-1106 or by determining the expression level or activity of CKId and CKIe in tumor samples. 
